Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thrombolytic agents--an overview

D C Gulba1, C Bode, M S Runge

  • 1Virchow Klinikum der Humboldt-Universität zu Berlin, Franz-Volhard-Klinik, Germany.

Annals of Hematology
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Usability and feasibility of E-nergEYEze: a blended vision-specific E-health based cognitive behavioral therapy and self-management intervention to reduce fatigue in adults with visual impairment.

BMC health services research·2023
Same author

Preliminary Study on Open Labelled Randomized Controlled Trial of the Safety and Efficacy of Hydroxychloroquine and Chloroquine Phosphate for the Treatment of Persons Infected with 2019 Coronavirus Disease in Nigeria.

West African journal of medicine·2023
Same author

The effectiveness of motivational interviewing on adherence to wearing orthopedic shoes in people with diabetes at low-to-high risk of foot ulceration: A multicenter cluster-randomized controlled trial.

Diabetes research and clinical practice·2023
Same author

Attitudes and experiences towards the application of motivational interviewing by podiatrists working with people with diabetes at high-risk of developing foot ulcers: a mixed-methods study.

Journal of foot and ankle research·2022
Same author

Using motivational interviewing combined with digital shoe-fitting to improve adherence to wearing orthopedic shoes in people with diabetes at risk of foot ulceration: study protocol for a cluster-randomized controlled trial.

Trials·2021
Same author

Pro- and anti-inflammatory macrophages express a sub-type specific purinergic receptor profile.

Purinergic signalling·2021
Same journal

Low- to moderate-dose thalidomide combination rescue after luspatercept failure in transfusion-dependent β-thalassemia: a real-world cohort study.

Annals of hematology·2026
Same journal

Real-world treatment patterns and outcomes in chronic lymphocytic leukemia: a multicenter retrospective study in Greece.

Annals of hematology·2026
Same journal

Comparative thromboembolic risk of romiplostim versus eltrombopag in immune thrombocytopenia: a propensity score-matched cohort study.

Annals of hematology·2026
Same journal

Impact of race on mutational profile and survival in acute myeloid leukemia: a single-institution experience (2014-2024).

Annals of hematology·2026
Same journal

Early versus standard anti-thymocyte globulin administration in haploidentical transplantation using post-transplant cyclophosphamide: a pilot comparative study.

Annals of hematology·2026
Same journal

Transcriptomic profiling of an in vivo diffuse large B-cell lymphoma model reveals molecular programs underlying CNS dissemination.

Annals of hematology·2026
See all related articles

Newer plasminogen activators, like tissue-type plasminogen activator (t-PA), offer improved thrombolytic therapy for conditions such as heart attack and blood clots. Research continues for even better treatments.

Area of Science:

  • Pharmacology
  • Biochemistry
  • Thromboembolic Disease Treatment

Background:

  • Thrombolysis is a standard treatment for acute myocardial infarction and other thromboembolic diseases.
  • Older plasminogen activators (streptokinase, urokinase) had limited efficacy and significant side effects.
  • The need for improved thrombolytic agents spurred the development of new plasminogen activators.

Purpose of the Study:

  • To review the biochemical and pharmacological properties of current and emerging plasminogen activators.
  • To compare the efficacy and safety of different generations of thrombolytic agents.
  • To highlight advancements in the treatment of thromboembolic disorders.

Main Methods:

  • Review of existing literature on plasminogen activators.

Related Experiment Videos

  • Comparison of clinical trial data for anistreplase and tissue-type plasminogen activator (t-PA).
  • Analysis of pharmacological profiles and clinical outcomes.

    • Main Results:

    • Tissue-type plasminogen activator (t-PA) has demonstrated clinical efficacy in large trials for myocardial infarction, pulmonary embolism, and deep vein thrombosis.
    • Anistreplase has not shown superiority over older agents like urokinase and streptokinase.
    • Ongoing research focuses on developing next-generation plasminogen activators with enhanced properties.

    Conclusions:

    • Tissue-type plasminogen activator (t-PA) is an established thrombolytic therapy.
    • Further research is essential to discover and develop plasminogen activators with improved safety and efficacy.
    • Advancements in thrombolytic agents continue to refine the treatment of thromboembolic diseases.